{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T11:02:56Z","timestamp":1779793376132,"version":"3.53.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100014824","name":"Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, India","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014824","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019125","name":"National Institute of Pharmaceutical Education and Research, Ahmedabad","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019125","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.dmd.2026.100275","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T16:39:11Z","timestamp":1773851951000},"page":"100275","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A drug-to-metabolite ratio-based quantitative analytical approach for evaluation of combination therapy through impact assessment of brigatinib on the pharmacokinetics of tazemetostat and its primary metabolite"],"prefix":"10.1016","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2414-5736","authenticated-orcid":false,"given":"Niraj","family":"Rajput","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karuna","family":"Chandnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarang","family":"Jadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6914-7057","authenticated-orcid":false,"given":"Pinaki","family":"Sengupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.dmd.2026.100275_bib1","doi-asserted-by":"crossref","first-page":"486","DOI":"10.2165\/00003088-199426060-00006","article-title":"Pharmacokinetic drug interactions with anticancer drugs","volume":"26","author":"Loadman","year":"1994","journal-title":"Clin Pharmacokinet"},{"issue":"8","key":"10.1016\/j.dmd.2026.100275_bib2","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(04)01528-1","article-title":"Drug interactions in oncology","volume":"5","author":"Beijnen","year":"2004","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.dmd.2026.100275_bib3","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s11096-010-9410-0","article-title":"Potential drug-drug interactions between anti-cancer agents and community pharmacy dispensed drugs","volume":"32","author":"Voll","year":"2010","journal-title":"Pharm World Sci"},{"issue":"5","key":"10.1016\/j.dmd.2026.100275_bib4","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/bjc.2013.48","article-title":"Prevalence of potential drug-drug interactions in cancer patients treated with oral anticancer drugs","volume":"108","author":"van Leeuwen","year":"2013","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.dmd.2026.100275_bib5","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1049\/iet-syb.2019.0116","article-title":"Efficient prediction of drug-drug interaction using deep learning models","volume":"14","author":"Kumar Shukla","year":"2020","journal-title":"IET Syst Biol"},{"issue":"4","key":"10.1016\/j.dmd.2026.100275_bib6","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ctrv.2007.02.003","article-title":"The role of nuclear receptors in pharmacokinetic drug-drug interactions in oncology","volume":"33","author":"Harmsen","year":"2007","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"10.1016\/j.dmd.2026.100275_bib7","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2174\/187569209788654005","article-title":"Activation of CAR and PXR by dietary, environmental and occupational chemicals alters drug metabolism, intermediary metabolism, and cell proliferation","volume":"7","author":"Hernandez","year":"2009","journal-title":"Curr Pharmacogenomics Pers Med"},{"issue":"13","key":"10.1016\/j.dmd.2026.100275_bib8","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.addr.2010.08.006","article-title":"Regulation of drug-metabolizing enzymes by xenobiotic receptors: PXR and CAR","volume":"62","author":"Tolson","year":"2010","journal-title":"Adv Drug Deliv Rev"},{"issue":"3","key":"10.1016\/j.dmd.2026.100275_bib9","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1517\/17425255.2013.754010","article-title":"Nuclear receptors PXR and CAR: implications for drug metabolism regulation, pharmacogenomics and beyond","volume":"9","author":"Chai","year":"2013","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"2","key":"10.1016\/j.dmd.2026.100275_bib10","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.toxlet.2015.03.015","article-title":"Expression of hepatic cytochrome P450s and UDP-glucuronosyltransferases in PXR and CAR double humanized mice treated with rifampicin","volume":"235","author":"Lee","year":"2015","journal-title":"Toxicol Lett"},{"issue":"3","key":"10.1016\/j.dmd.2026.100275_bib11","doi-asserted-by":"crossref","first-page":"332","DOI":"10.4103\/wjtcm.wjtcm_52_21","article-title":"Panax notoginseng saponins increases the blood concentration of nifedipine by inhibiting CYP3A4 enzyme through PXR- and CAR-mediated pathway","volume":"7","author":"Li","year":"2021","journal-title":"World J Tradit Chin Med"},{"key":"10.1016\/j.dmd.2026.100275_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2022.154097","article-title":"Panaxytriol upregulates CYP3A4 expression based on the interaction of PXR, CAR, HSP90\u03b1, and RXR\u03b1","volume":"101","author":"Zhang","year":"2022","journal-title":"Phytomedicine"},{"issue":"5","key":"10.1016\/j.dmd.2026.100275_bib13","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1124\/dmd.30.5.608","article-title":"Induction of cytochrome P450 3A4 in primary human hepatocytes and activation of the human pregnane X receptor by tamoxifen and 4-hydroxytamoxifen","volume":"30","author":"Desai","year":"2002","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.dmd.2026.100275_bib14","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00280-008-0842-3","article-title":"Nuclear receptor mediated induction of cytochrome P450 3A4 by anticancer drugs: a key role for the pregnane X receptor","volume":"64","author":"Harmsen","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"issue":"8","key":"10.1016\/j.dmd.2026.100275_bib15","article-title":"Potential anti-cervical carcinoma drugs with agonist and antagonist AhR\/PXR activities","volume":"4","author":"Zidi","year":"2016","journal-title":"Med Res Arch"},{"issue":"7","key":"10.1016\/j.dmd.2026.100275_bib16","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.3390\/cells9071641","article-title":"The anti-cancer drug dabrafenib is a potent activator of the human pregnane X receptor","volume":"9","author":"Creusot","year":"2020","journal-title":"Cells"},{"issue":"5","key":"10.1016\/j.dmd.2026.100275_bib17","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1111\/cts.13229","article-title":"Effect of enzalutamide on PK of P-gp and BCRP substrates in cancer patients: CYP450 induction may not always predict overall effect on transporters","volume":"15","author":"Poondru","year":"2022","journal-title":"Clin Transl Sci"},{"issue":"9","key":"10.1016\/j.dmd.2026.100275_bib18","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1007\/s40262-020-00882-2","article-title":"Pharmacokinetic drug-drug interaction of apalutamide, part 1: clinical studies in healthy men and patients with castration-resistant prostate cancer","volume":"59","author":"Duran","year":"2020","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"10.1016\/j.dmd.2026.100275_bib19","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1177\/1060028018824578","article-title":"Brigatinib: novel ALK inhibitor for non-small-cell lung cancer","volume":"53","author":"Spencer","year":"2019","journal-title":"Ann Pharmacother"},{"issue":"6","key":"10.1016\/j.dmd.2026.100275_bib20","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.jsps.2018.04.010","article-title":"A comprehensive review on brigatinib-a wonder drug for targeted cancer therapy in non-small cell lung cancer","volume":"26","author":"Bedi","year":"2018","journal-title":"Saudi Pharm J"},{"key":"10.1016\/j.dmd.2026.100275_bib21","series-title":"Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy","first-page":"45","article-title":"ALK tyrosine kinase inhibitors in drug sensitization","author":"Wu","year":"2019"},{"issue":"3","key":"10.1016\/j.dmd.2026.100275_bib22","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3390\/cells11030313","article-title":"Nuclear receptor PXR in drug-induced hypercholesterolemia","volume":"11","author":"Karpale","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.dmd.2026.100275_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.fct.2024.114785","article-title":"Identification and characterization of the rat in-vivo and in-vitro metabolites of tazemetostat using LC-QTOF-MS","volume":"190","author":"Rajput","year":"2024","journal-title":"Food Chem Toxicol"},{"issue":"1","key":"10.1016\/j.dmd.2026.100275_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-020-07667-7","article-title":"EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells","volume":"20","author":"Gong","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.dmd.2026.100275_bib25","series-title":"Bioanalytical Method Validation and Study Sample Analysis","year":"2022"},{"issue":"15","key":"10.1016\/j.dmd.2026.100275_bib26","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.4155\/bio-2022-0123","article-title":"Bioanalysis by LC-MS\/MS and preclinical pharmacokinetic interaction study of ribociclib and oleanolic acid","volume":"14","author":"Sahu","year":"2022","journal-title":"Bioanalysis"},{"key":"10.1016\/j.dmd.2026.100275_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.ab.2023.115084","article-title":"LC-QQQ-MS based intracellular quantification of bictegravir in peripheral blood mononuclear cells and plasma","volume":"667","author":"Jadav","year":"2023","journal-title":"Anal Biochem"},{"key":"10.1016\/j.dmd.2026.100275_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2023.123678","article-title":"Development and validation of a bioanalytical method for the quantification of CHF6550 and its metabolite (CHF6671) in rat plasma and lung homogenate using LC-MS\/MS","volume":"1222","author":"Vezzelli","year":"2023","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"2","key":"10.1016\/j.dmd.2026.100275_bib29","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/FTD.0000000000000484","article-title":"Development and validation of a bioanalytical method to quantitate enzalutamide and its active metabolite N-desmethylenzalutamide in human plasma: application to clinical management of patients with metastatic castration-resistant prostate cancer","volume":"40","author":"Benoist","year":"2018","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.dmd.2026.100275_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2021.114360","article-title":"UPLC-MS\/MS method for the determination of lenvatinib in rat plasma and its application to drug-drug interaction studies","volume":"206","author":"Cui","year":"2021","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.dmd.2026.100275_bib31","series-title":"Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers: Guidance for Industry","year":"2005"},{"issue":"2","key":"10.1016\/j.dmd.2026.100275_bib32","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/0976-0105.177703","article-title":"A simple practice guide for dose conversion between animals and human","volume":"7","author":"Nair","year":"2016","journal-title":"J Basic Clin Pharm"},{"key":"10.1016\/j.dmd.2026.100275_bib33","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.yrtph.2017.10.029","article-title":"Assessment of preclinical pharmacokinetics and acute toxicity of pioglitazone and telmisartan combination","volume":"91","author":"Sengupta","year":"2017","journal-title":"Regul Toxicol Pharmacol"},{"key":"10.1016\/j.dmd.2026.100275_bib34","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.jpba.2019.05.069","article-title":"An LC-MS\/MS spectrometry method for the simultaneous determination of rosuvastatin and irbesartan in rat plasma: insight into pharmacokinetic and drug-drug interaction studies","volume":"174","author":"Elgawish","year":"2019","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.dmd.2026.100275_bib35","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jpba.2013.06.014","article-title":"Characterization of four new photodegradation products of hydroxychloroquine through LC-PDA, ESI-MSn and LC-MS-TOF studies","volume":"84","author":"Saini","year":"2013","journal-title":"J Pharm Biomed Anal"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955626000449?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955626000449?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T10:14:45Z","timestamp":1779790485000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955626000449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0090955626000449"],"URL":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100275","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A drug-to-metabolite ratio-based quantitative analytical approach for evaluation of combination therapy through impact assessment of brigatinib on the pharmacokinetics of tazemetostat and its primary metabolite","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100275","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100275"}}